news

CUPERTINO, Calif., Oct. 15, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the BIO Investor Forum on Wednesday, October 21 at 9:30 a.m. Pacific time.  The conference is being held at the Parc55 Hotel in San Francisco.  Investors and analysts that are attending the conference may […]

CUPERTINO, Calif., Aug. 27, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences.  James E. Brown, President and CEO, will present at the Rodman & Renshaw Investment Conference on Thursday, September 10 at 10:00 a.m. Eastern time. The conference is being held at the

CUPERTINO, Calif., Aug. 3, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2015.  Total revenues were $4.4 million and net loss was $5.5 million for the three months ended June 30, 2015 as compared to total revenues of $4.6 million and net loss of $5.5 million for the

CUPERTINO, Calif., July 24, 2015 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 3, 2015 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio

CUPERTINO, Calif., June 29, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8 at 11:45 a.m. Eastern Time.  The conference is being held at Le Parker Meridien Hotel in New York City.  Investors and analysts

CUPERTINO, Calif., June 23, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced that, based on feedback from the FDA, it plans to conduct a new POSIDUR™ (SABER®-Bupivacaine) Phase 3 clinical trial consisting of approximately 300 patients undergoing laparoscopic cholecystectomy (gallbladder removal) surgery.  DURECT anticipates beginning the trial in the fall of 2015 and expects that it

CUPERTINO, Calif., May 18, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT’s Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic

CUPERTINO, Calif., April 30, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2015.  Total revenues were $4.8 million and net loss was $4.9 million for the three months ended March 31, 2015 as compared to total revenues of $6.3 million and net loss of $3.6 million for the

CUPERTINO, Calif., April 22, 2015 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, April 30, 2015 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio

CUPERTINO, Calif., March 30, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT’s Epigenomic Regulator Program.  DUR-928 is an endogenous, small-molecule, new chemical entity (NCE) that may have broad applicability in metabolic diseases such